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S U M M A R Y
Objectives: To describe the clinical characteristics and prognostic factors of hematological patients
affected by Nocardia spp infections.
Methods: We retrospectively evaluated all the cases diagnosed in four Italian institutions.
Results: Between 2002 and 2012, 10 cases of nocardiosis were recorded. The median age of the patients
was 66 years (range 24–85 years). The underlying hematological disease was a lymphoproliferative
disorder in all but two patients. Eight patients (80%) showed active underlying hematological disease,
relapsed or refractory in ﬁve (50%); one patient had a history of previous allogeneic bone marrow
transplantation. Eight patients (80%) were on steroid therapy; lymphopenia was present in 8/10 (80%)
patients. All patients showed lung involvement. Six patients were affected by disseminated nocardiosis.
Three patients (30%) were nocardemic and three (30%) showed central nervous system involvement.
Skin, lymph nodes, and bone were involved in one patient each. The median overall survival was 65 days.
Older age, a longer period between hematological diagnosis and Nocardia spp infection, and relapsed/
refractory hematological disease were associated with a worse prognosis.
Conclusions: Although rare, nocardiosis should be considered in the differential diagnosis of pulmonary
and central nervous system lesions among hematological patients. Lymphoproliferative disorders,
prolonged steroid treatment, lymphopenia, and active hematological disease are the conditions that are
worth considering as predisposing factors for the development of this disease.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Infections due to Nocardia spp are rare; localized skin forms are
often seen among categories with limited exposure, such as
agricultural workers.1,2 Although uncommon, disseminated infec-
tions are severe and life-threatening and affect mainly immuno-
deﬁcient patients.3 The most common localization is the lung, but
central nervous system (CNS), soft tissue, blood, and lymph nodes
are also involved in disseminated nocardiosis.1,2
Due to the rarity of the disease and to the relative difﬁculty and
slowness of growing cultures, the diagnosis of Nocardia spp
infection may be underestimated. Differential diagnoses include
bacterial lung abscess, aspergillosis or other invasive mould* Corresponding author.
E-mail addresses: chiara.cattaneo@libero.it, chiara.cattan@gmail.com
(C. Cattaneo).
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http://dx.doi.org/10.1016/j.ijid.2013.01.013infections, actinomycosis, tuberculosis, and other malignan-
cies.3–5
Large series of nocardiosis are uncommon and often refer to
heterogeneous patients with different underlying diseases.3,6–9
Chronic obstructive pulmonary disease (COPD), renal failure, and
diabetes mellitus (DM) are predisposing factors, as well as
immunodeﬁciency following prolonged steroid therapy, autoim-
munity, HIV positivity, cancer, and solid organ or bone marrow
transplantation. Of note, mortality due to nocardiosis ranges
between 7% and 44%;2 disseminated infections, with nocardemia
and brain abscesses, are responsible for an even higher death rate.3
Hematological patients are considered a risk category for
nocardiosis because of intrinsic and therapy-related immunodeﬁ-
ciency. The recent introduction in clinical practice of new, highly
immunosuppressive therapeutic agents in the non-transplant
setting may be responsible for the increased incidence of
nocardiosis observed during recent years.2,10 In order to better
identify the clinical and prognostic characteristics of nocardiosis,
as well as the type of underlying immunodeﬁciency predisposingses. Published by Elsevier Ltd. All rights reserved.
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tively collected data of cases diagnosed in different Italian
hematology units. The exposure to antibiotic prophylaxis and
the therapeutic approach were also evaluated.
2. Patients and methods
2.1. Patients and setting
Between October 2002 and November 2012, patients with a
diagnosis of Nocardia spp infection admitted to four Italian
hematology wards of tertiary care centers or university hospitals
participating in the SEIFEM (Sorveglianza Epidemiologica Infezioni
Fungine nelle Emopatie Maligne) group were included in the study.
The study was approved by the ethics committee.
The clinical charts of all patients included in this study were
retrospectively reviewed. Information was analyzed on age, gender,
habits (smoking), place of residence, professional exposure (type of
job), comorbidities (DM, COPD, chronic renal failure), time from
hematological disease to Nocardia infection, underlying immuno-
compromised conditions (including underlying hematological
disease, neutropenia and lymphopenia, history of immunosuppres-
sant drug use, and corticosteroid therapy), possible prophylaxis with
co-trimoxazole, type of therapy delivered, and outcome.
2.2. Deﬁnitions
A diagnosis of nocardiosis required a histological ﬁnding or at
least one positive culture from respiratory samples (including
expectorated sputum and bronchoalveolar lavage), blood, or abscess
drainage, and the presence of pertinent clinical symptoms and signs.
Nocardiae were isolated from BACTEC blood culture broth media;
nocardiae from tissue specimens, as well as bronchoalveolar lavage
and sputum samples, were isolated from blood agar plates. If a
Nocardia infection was suspected, a Kinyoun acid-fast stain was
performed. Molecular techniques were not routinely performed.
Infections by pathogens other than Nocardia were also
excluded with standard microbiological tests.
‘Pulmonary’ nocardiosis was deﬁned when signs and symptoms
were limited to the lungs; ‘disseminated’ nocardiosis was deﬁned
when the isolation of Nocardia spp was demonstrated from
specimens from two or more non-contiguous organs, such as
lung, lymph node, skin, and brain, or from blood.
2.3. Statistical analysis
Analyses of differences between groups were performed using
the Mann–Whitney test or Fisher’s exact test. A p-value of <0.05
was considered to be statistically signiﬁcant.Table 1
Patient characteristics (sex, age, underlying hematological disease, status of hematolog
Patient Sex/age, years Underlying hematological disease 
1 Male/67 MF + peripheral T-NHL 
2 Male/71 MCD 
3 Male/71 HES 
4 Female/85 DLCL 
5 Male/70 ITP 
6 Male/63 ITP + B-CLL 
7 Female/65 SS 
8 Male/62 MCL 
9 Male/55 HCL 
10 Male/24 DLCL 
CLL, chronic lymphocytic leukemia; DLCL, diffuse large cell lymphoma; HCL, hairy ce
purpura; MCL, mantle cell lymphoma; MCD, multicentric Castleman disease; MF, mye
a From ITP diagnosis.3. Results
3.1. Characteristics of patients
Between 2002 and 2012, 10 cases of nocardiosis were observed
in four different hematology centers.
The male/female ratio was 8/2; the median age at diagnosis of
Nocardia infection was 66 years (range 24–85 years). Only one
patient had professional exposure (farmer) and 4/10 were
smokers. The majority of them lived in the countryside (7/10).
Comorbidities were reported in 5/10 patients (two DM, two
chronic renal failure, and one COPD).
Underlying hematological diseases were B cell non-Hodgkin
lymphoma (NHL) (n = 3), T-NHL + myeloﬁbrosis (n = 1), multi-
centric Castleman disease (n = 1), hairy cell leukemia (n = 1),
idiopathic thrombocytopenic purpura (ITP) (n = 1), chronic lym-
phocytic leukemia + ITP (n = 1), hypereosinophilic syndrome (HES)
(n = 1), and Se´zary syndrome (n = 1). One patient (B-NHL)
developed nocardiosis after allogeneic stem cell transplantation
(alloSCT).
The median time from the diagnosis of the hematological
disease to Nocardia infection was 5 months (range 0–30
months). All but two patients (80%) showed active underlying
hematological disease and ﬁve were considered (50%) relapsed
or refractory.
In only one patient was the identiﬁcation of the species
available (Nocardia asteroides); susceptibility data were available
only in two cases and revealed resistance to ciproﬂoxacin in both
cases and to amoxicillin–clavulanate in one. Both cases were
susceptible to linezolid, amikacin, imipenem, and co-trimoxazole.
Table 1 shows the patient clinical characteristics.
3.2. Previous treatment and immunological status
Eight out of 10 patients (80%) were on corticosteroid therapy,
started at least 3 weeks before the diagnosis of nocardiosis. The
median duration of corticosteroid therapy was 3.5 months (range
3–11 months) and the median dose delivered was 25 mg/day of
prednisone or equivalent (range 10–50 mg/day).
Two patients (20%) were receiving hydroxyurea and one patient
received anthracycline-containing chemotherapy for three cycles 3
months before the diagnosis of nocardiosis and then only steroid
therapy. One patient (10%) received immunochemotherapy
(rituximab + anthracycline-containing chemotherapy) immedi-
ately before Nocardia infection. One patient (10%), affected by
Se´zary syndrome, was on photopheresis. Concerning co-trimox-
azole prophylaxis, only two patients (20%) were receiving this. The
single alloSCT patient was receiving prednisone and cyclosporine
because of graft versus host disease (GVHD).ical disease, and time from hematological disease to nocardiosis)
Status Time from hematological disease
to nocardiosis (months)
Refractory 18
Refractory 18
Refractory 10
Refractory 6
Refractory 3
Partial remission 3a
Diagnosis 4
Disease beginning 1
Disease beginning 0
Complete remission 30
ll leukemia; HES, hypereosinophilic syndrome; ITP, idiopathic thrombocytopenic
loﬁbrosis; NHL, non-Hodgkin lymphoma; SS, Se´zary syndrome.
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of <0,5  109/l) was present in only one patient, whereas
lymphopenia (lymphocyte count <1,5  109/l) was present in 8/
10 (80%). The median lymphocyte count was 0,5  109/l (range
0,12–2,4  109/l) and four patients showed a lymphocyte count of
<0,5  109/l.
3.3. Clinical presentation
Fever was present in all but two patients (8/10, 80%) at
diagnosis of Nocardia spp infection, cough in 6/10 (60%), and
thoracic pain in two cases (20%). Neurological signs were present in
two patients (20%) and hemoptysis in one (10%).
All patients affected by nocardiosis showed lung involvement;
in 4/10 cases (40%) it was the only site of infection (pulmonary
nocardiosis). Radiological examinations showed non-speciﬁc
inﬁltrates in two (20%) cases, isolated or multiple nodular lesions
in four (40%), and multiple lesions with cavitations in four (40%).
Figure 1 shows the radiological ﬁndings for one patient with
aspeciﬁc pulmonary inﬁltrates.
Six patients were affected by disseminated nocardiosis. Three
patients (30%) were nocardemic and three (30%) showed CNS
involvement. Skin, lymph nodes, and bone were involved in one
patient each.
A concomitant diagnosis of pulmonary aspergillosis according
to the EORTC/MSG study group criteria11 was present in two (20%)
patients: one probable, with typically cavitated lesions and a
galactomannan index of 1, and one possible, with non-speciﬁc
pulmonary inﬁltrates and culture test positivity for Aspergillus
fumigatus and Aspergillus niger.
Table 2 details the clinical presentation and site of diagnosis of
Nocardia spp infection.Figure 1. Aspeciﬁc pulmonary inﬁltrates: X-ray of
Table 2
Clinical presentation and site of diagnosis (symptoms and signs, organ/tissue involvem
Patient Symptoms/signs Localization
1 Fever Lung, lymph
2 Fever, cough, neurological syndrome Lung 
3 Fever, cough Lung, blood
4 Fever, cough Lung 
5 Fever, hemoptysis Lung, blood
6 Neurological syndrome CNS, lung, b
7 Fever, dyspnea, thoracic pain Lung, blood
8 Cough, dyspnea Lung 
9 Fever Lung, CNS 
10 Fever, cough, thoracic pain Lung 
BAL, bronchoalveolar lavage; CNS, central nervous system; IPA, invasive pulmonary as3.4. Treatment and outcome
Treatment approaches, duration of therapy, and outcomes are
reported in Table 3. Four out of the six patients who died and two of
the four patients who survived received monotherapy as ﬁrst-line
treatment, which was changed to combination therapy in three
cases (two patients who died and one who survived).
Combination therapy was initially given to two of four
patients who survived (carbapenems + amikacin, and carbape-
nems + co-trimoxazole, one case each) and in two patients with
a fatal outcome (co-trimoxazole + imipenem, and imipenem +
amikacin).
Six of 10 (60%) patients died after a median time of 45 days
(range 2–70 days) from diagnosis of nocardiosis. In four cases (50%)
nocardiosis was considered the cause of death; two of them were
also affected by aspergillosis. One patient (10%) died of uncon-
trolled hematological disease with nocardiosis.
The median overall survival of all the patients was 65 days from
nocardiosis, after a median follow-up of 360 days. The 3-year
overall survival was 40%.
The main differences between the patients who survived and
those who died were evaluated among the nine non-alloSCT
patients and are reported in Table 4. Surviving patients were
younger than those who died (median 62.5 years vs. 71 years,
respectively; p = 0.0159) and had a shorter period between
hematological diagnosis and Nocardia spp infection (median 2
months vs. 10 months, respectively; p = 0.0317). Moreover, none of
patients who survived had relapsed or refractory hematological
disease, whereas all those who died did (p = 0.0079). All the
patients with a fatal outcome were on prolonged steroid therapy,
whereas only two out of four who survived were. The absolute
lymphocyte count did not seem to be an adverse prognostic factor the thorax and computed tomography scan.
ent, site of Nocardia isolation, and concomitant infections)
 Isolation site Concomitant infection
 nodes Lymph node aspirate Probable IPA
BAL -
, CNS Blood culture -
Sputum Possible IPA
 Blood culture -
one Brain abscess -
, skin Blood culture -
Sputum -
BAL -
BAL + sputum -
pergillosis.
Table 3
Treatment approaches and outcome of patients (type of therapy, duration of therapy, evolution, and overall survival from the diagnosis of nocardiosis)
Patient Therapy Duration (days) Evolution Overall survival (days)
1 SXT ! IPM + AMK 70 Died 70
2 SXT ! SXT + IPM 36 Died 39
3 SXT + IPM 50 Died 50
4 IPM 1 Died 2
5 SXT 3 Died 6
6 MEM + AMK ! MEM + VAN ! MEM + SXT 90+ Alive and well 1440+
7 IPM + SXT 60+ Alive and well 180+
8 SXT 35+ Alive and well 360+
9 AMK ! SXT + CRO 180 Alive and well 360+
10 IPM + AMK 30+ Died 60
AMK, amikacin; CRO, ceftriaxone; IPM, imipenem; MEM, meropenem; SXT, trimethoprim–sulfamethoxazole; VAN, vancomycin.
Table 4
Comparison of prognostic factors for fatal and non-fatal disease in non-allogeneic stem cell transplant patients (n = 9)
Survived (n = 4) Died (n = 5) p-Value
Age, years, median (range) 62.5 (55–65) 71 (67–85) 0.0159
Comorbidities 3/4 2/5 NS
Relapsed/refractory 0/4 5/5 0.0079
Time from hematological disease to nocardiosis, months, median (range) 2 (0–4) 10 (3–18) 0.0317
Lymphocyte count, 109/l, median (range) 0.215 (0.120–1.870) 0.580 (0.250–2.400) NS
Steroid therapy 2/4 5/5 NS
Involvement of >1 site 3/4 3/5 NS
Concomitant infections 0/4 2/5 NS
First-line combination therapy 2/4 1/5 NS
NS, not signiﬁcant.
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who died and survived, respectively).
4. Discussion
Hematological cancer patients are at risk for opportunistic
infections, causing subacute or chronic life-threatening disease.
The frequent use of monoclonal antibodies and purine analogs,
responsible for impaired cell-mediated immunity, has determined
an increase in opportunistic infections other than moulds, such as
Pneumocystis jirovecii and cytomegalovirus infections, including
among hematological patients not undergoing alloSCT. Nocardia
spp infections should also be considered as a possible opportunistic
pathogen affecting hematologic cancer patients. Its actual inci-
dence may be underestimated and microbiologists should always
be informed of the possibility of Nocardia infection in order to
optimize microscopic and culture methods for its detection.
In our series we observed only 10 cases in 10 years among the
SEIFEM centers, which could be due to misdiagnosis or to actual
rarity. The majority of patients were affected by lymphoprolifera-
tive diseases; in the remaining two cases (one HES and one ITP) a
prolonged corticosteroid therapy was ongoing, in line with the
results of other series.12,13 Nocardiosis seems to be a disease of
older hematological patients, as most of non-transplanted subjects
with Nocardia spp infection were over 60 years of age. Neutropenia
was not frequent in our series and none of patients with
nocardiosis were affected by acute leukemia. Lymphopenia,
observed in 8/10 cases, was the other main characteristic of most
patients. Even if no pathognomonic clinical characteristics exist,
nocardiosis should be suspected in lymphopenic patients with
pulmonary inﬁltrates, particularly if associated with brain abscess,
in order to avoid a delay in diagnosis and treatment. Invasive
fungal diseases, but also bacteria causing necrotizing pneumonia
(such as Pseudomonas aeruginosa, Staphylococcus aureus, or
anaerobic bacteria), should be considered in the differential
diagnosis. Only one patient received alloSCT, thus conﬁrming that
this disease may also affect patients with less pronouncedimmunosuppression. The infection-related mortality in our series
was 60%, similar to data reported in the literature for pulmonary
and systemic infections.3 Nocardemia seems to be a very severe
condition, as two of three nocardemic patients died and one was
admitted to the intensive care unit. As already reported,1,2
symptoms related to Nocardia spp infections were also often
non-speciﬁc in our series: cough, hemoptysis, and neurological
ﬁndings, which are frequently observed in other opportunistic
infections. The radiological presentation of pulmonary nocardiosis,
as well as brain abscess, consisted of isolated or, more often,
multiple lesions (8/10) without pathognomonic characteristics. In
particular, pulmonary nocardiosis presented with non-speciﬁc,
nodular or escavated lesions, like invasive fungal disease or other
conditions (tuberculosis, necrotizing pneumonia).
Only two out of 10 patients were receiving co-trimoxazole as P.
jirovecii pneumonia prophylaxis. The issue of co-trimoxazole
prophylaxis for preventing nocardiosis is still a matter of debate.
Minero et al.7 reported that 14.2% of patients with nocardiosis
were receiving co-trimoxazole prophylaxis and concluded that it
should not be considered a guarantee for complete protection,
although some authors14 suggest that co-trimoxazole may prevent
dissemination. Breakthrough Nocardia spp infections, however,
seem to maintain susceptibility to co-trimoxazole.15 The treatment
approach, as well as the number of involved sites, did not inﬂuence
the prognosis. The treatment choice was extremely heteroge-
neous; however, all but one patient evaluable for treatment (one
patient too early) received co-trimoxazole during the course of
treatment. Disseminated nocardiosis in immunocompromised
patients should initially be treated with combination antibiotic
therapy, preferably a three-drug combination therapy (imipenem
+ amikacin + co-trimoxazole or ceftriaxone),2 although no speciﬁc
guidelines have been published. Concerning the number of
involved sites, in two of six patients who died, the lung was the
only site of infection, and three of four who survived showed a
disseminated nocardiosis. Among non-alloSCT patients, refractory
hematological disease, age, and time from hematological diagnosis
to nocardiosis were actually risk factors predictive of death.
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logical data concerning identiﬁcation of species and susceptibility
data largely missing, and absence of central review of medical
chart information), we can conclude that, although rare, nocar-
diosis should be considered in the differential diagnosis of
pulmonary and CNS lesions among hematological patients, even
in those not undergoing alloSCT. Nocardia spp infections are not
typical for leukemic patients, in whom invasive mould infections
are mainly responsible for nodular pulmonary lesions. Lympho-
proliferative disorders, prolonged steroid treatment, lymphopenia,
and active hematological disease are the conditions that are worth
considering as predisposing factors for developing Nocardia spp
infections, which are to be considered curable for those patients
starting adequate antibiotic therapy and with a non-refractory
underlying hematological disease.
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